Industry News
21 Approved ADCs Worldwide: The Ultimate …
As of 2025, a total of 21 ADC drugs have been approved globally.
List of FDA Approved PEGylated Drugs Up t…
History of PEGylated drugs, list of FDA approved PEGylated drugs, advantages and challenges of PEGylation.
PEG Linkers in Aptamer Drug Development
Discover how PEG linkers improve aptamer stability, pharmacokinetics, and therapeutic performance. Learn from approved PEGylated aptamer drugs and emerging applications.
Complement Inhibitors: FDA-Approved Drugs…
Explore complement inhibitors, FDA-approved drugs, and how PEGylation improves stability, half-life, and therapeutic performance.
Long-Acting Growth Hormones: The Role of …
The development of weekly long-acting growth hormone (LAGH) has significantly improved treatment adherence and the overall patient experience.
DAC (Degrader-Antibody Conjugates): Next …
Beyond ADCs, Degrader-Antibody Conjugates (DACs) represent this next frontier. BMS-986497 (ORM-6151) is under clinical trials.
Antibody-Oligonucleotide Conjugates (AOCs…
Antibody–Oligonucleotide Conjugate (AOC) technology has emerged as a promising strategy. By leveraging the tissue-specific binding affinity of monoclonal antibodies or their functional fragm…
Monodisperse PEG in Modern Drug Developme…
Learn how monodisperse PEG improves drug precision, safety, and consistency in ADCs, peptides, and FDA-approved therapies.
2025 FDA Drug Approvals: A Landmark Year …
With 46 new drug approvals, the agency stayed right on track with its usual pace, but the real story is in what they approved.
In Vivo CAR-T Cell Therapy: Current Strat…
This article reviews in vivo CAR-T approaches, delivery vectors, clinical pipelines, and how the field is evolving beyond ex vivo CAR-T.
sales@huatengusa.com
+86 0731 89916275